Education
About Us
Working with TipRanks
Follow Us
Avita Medical Ltd (RCEL)
:RCEL
RCEL Stock Chart & Stats
$4.12
-$5.13(-36.49%)
At close: 4:00 PM EST
$4.12
-$5.13(-36.49%)
Day’s Range― - ―
52-Week Range$3.36 - $14.16
Previous CloseN/A
Volume824.49K
Average Volume (3M)225.57K
Market Cap
$93.17M
Enterprise ValueN/A
Total Cash (Recent Filing)$15.69M
Total Debt (Recent Filing)$44.59M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Feb 19, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding26,618,935
10 Day Avg. Volume183,363
30 Day Avg. Volume225,572
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)73.64
Price to Sales (P/S)5.16
P/FCF Ratio-5.69
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$7.50Price Target Upside82.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical SuccessThe recently presented clinical data highlight Avita's RECELL and Cohealyx offerings, encouraging commercial success.
Cost ReductionTo achieve new profitability goals, Avita reduced its operating expenses by roughly $2.4M and expects to see similar or greater levels of savings in each of the upcoming quarters.
Product Portfolio ExpansionAvita has set its sights on 2025 being a transformational year driven by portfolio expansion opportunities and growth of the legacy RECELL platform.
Bears Say
CEO Transition UncertaintyThe CEO transition adds uncertainty, as the company looks for new leadership both internally and externally.
Financial ChallengesRCEL's limited cash on hand, current operating cash burn, need for additional capital, and limits on how many shares can be issued exacerbate the downside risk.
Revenue Guidance ReductionRCEL lowered FY25 guidance to $70M-$74M, reflecting expected lower demand and utilization.
Avita Medical News
RCEL FAQ
What was Avita Medical Ltd’s price range in the past 12 months?
Avita Medical Ltd lowest stock price was $3.36 and its highest was $14.16 in the past 12 months.
What is Avita Medical Ltd’s market cap?
Avita Medical Ltd’s market cap is $93.17M.
When is Avita Medical Ltd’s upcoming earnings report date?
Avita Medical Ltd’s upcoming earnings report date is Feb 19, 2026 which is in 103 days.
How were Avita Medical Ltd’s earnings last quarter?
Avita Medical Ltd released its earnings results on Nov 06, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.332 by -$0.128.
Is Avita Medical Ltd overvalued?
According to Wall Street analysts Avita Medical Ltd’s price is currently Undervalued.
Does Avita Medical Ltd pay dividends?
Avita Medical Ltd does not currently pay dividends.
What is Avita Medical Ltd’s EPS estimate?
Avita Medical Ltd’s EPS estimate is -0.31.
How many shares outstanding does Avita Medical Ltd have?
Avita Medical Ltd has 26,618,935 shares outstanding.
What happened to Avita Medical Ltd’s price movement after its last earnings report?
Avita Medical Ltd reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.332. Following the earnings report the stock price went up 10.882%.
Which hedge fund is a major shareholder of Avita Medical Ltd?
Currently, no hedge funds are holding shares in RCEL
Avita Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.50 (82.04% Upside)
$7.50 (82.04% Upside)
Blogger Sentiment
Bullish
RCEL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 14.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $113.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.1%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.10%
12-Months-Change
Fundamentals
Return on Equity
-935.73%
Trailing 12-Months
Asset Growth
-33.81%
Trailing 12-Months
Company Description
Avita Medical Ltd
Avita Medical (RCEL) is a biotechnology company focused on regenerative medicine, particularly in the field of wound care and skin regeneration. The company specializes in developing innovative products derived from human tissue, primarily its flagship product, the RECELL System, which enables the rapid preparation of a patient’s own skin cells for the treatment of burns, chronic wounds, and other skin defects. Avita Medical operates in the healthcare sector, aiming to improve outcomes for patients while reducing the costs associated with traditional skin grafting methods.
RCEL Company Deck
RCEL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in reimbursement issues and cost management, alongside strategic expansions in Europe. However, these positive developments were offset by notable revenue declines, reduced revenue guidance, and financial adjustments indicating ongoing challenges. Despite improvements in operational efficiency and cash management, the financial outlook remains cautious.View all RCEL earnings summariesRCEL Revenue Breakdown
99.27% Commercial sales
0.67% Services for emergency preparedness
0.07% Deferred commercial revenue
RCEL Stock 12 Month Forecast
Average Price Target
$7.50
▲(82.04% Upside)
Technical Analysis
Ownership Overview
1.37% Insiders
8.66% Mutual Funds
0.29% Other Institutional Investors
82.78% Public Companies and
Individual Investors